Clinical trials: Re-irradiation
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults.
- Trial name
- NCT06305910
- Testing
- Treatment with CD200AR-L
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OX2 Therapeutics
Non-small Cell Lung Cancer
Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease
As one of the few centers, MAASTRO also aggressively re-treats patients with recurrent non-small cell lung cancer. Even after primary radical treatment to high doses, re-irradiation (with concurrent chemotherapy) is also given in…
- Trial name
- NCT01941303
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Maastricht Radiation Oncology
Pediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine Glioma
Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children
Although DIPG is not curable, re-irradiation with a modest total dose and short treatment time provides good palliation of symptoms, improves quality of life, delays disease progression and has minimal and manageable toxicity.
- Trial name
- NCT01777633
- Testing
- Palliative re-irradiation for progressive DIPG in children
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Hadassah Medical Organization
Brain Cancer
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy.
- Trial name
- NCT01469247
- Testing
- Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent High-grade Glioma
AsiDNA Children, Adolescents and Young Adults
HGG comprises diffuse midline gliomas (DMG), including diffuse infiltrating brainstem glioma (DIPG), characterised by histone gene mutations, as well as non-DM HGGs mainly in non-midline supratentorial areas, with distinct…
- Trial name
- AsiDNA (NCT05394558)
- Testing
- AsiDNA
- Where
- 10 sites in France
- Volunteers
- 8 people
- Sponsor
- Institut Curie
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that…
- Trial name
- NCT06288113
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
RE-irradiation of Diffuse MIdline Glioma paTients
The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG).
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, Diffuse Glioma, Pontine Tumors
- Trial name
- REMIT (NCT06093165)
- Testing
- Re-irradiation
- Volunteers
- 59 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Brain Tumor, Recurrent, Glioblastoma Multiforme
A Phase I/II Study of the Photon Radiosurgery System
The standard treatment for children with brain tumors is surgical removal of the tumor followed by radiation to the brain and chemotherapy (medicines) given to shrink any remaining tumor or to prevent tumor from growing back.
- Trial name
- NCT00179907
- Testing
- Photon Radiosurgery System (Intrabeam)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Radiotherapy Side Effect, Radiation Toxicity
Curatively Intended Thoracic Reirradiation
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates.
- Conditions
- Radiotherapy Side Effect, Radiation Toxicity, Oncology, Lung Cancer
- Trial name
- CureLung (NCT06950073)
- Testing
- Radiotherapy
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
DIPG, Brain Tumor, Pediatric, Recurrent
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require further treatment.
- Conditions
- DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity
- Trial name
- NCT04670016
- Testing
- This study does not include an intervention.
- Where
- 13 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Ependymoma
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
The primary purpose of this study is to investigate whether surgery and re-irradiation will help treat ependymoma that has come back after initial treatment.
- Trial name
- NCT02125786
- Testing
- Irradiation, Surgery, ^1^8F-Fluorodeoxyglucose
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
Re-Irradiation of Progressive or Recurrent DIPG
This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
- Trial name
- NCT03126266
- Testing
- re-irradiation
- Where
- 18 sites in Australia, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- University of Calgary
Recurrent Nasopharyngeal Carcinoma
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
We aim, in this study, to examine whether reduction of FLT PET derived SUV before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal…
- Trial name
- NCT03689556
- Testing
- FLT PET/CT
- Volunteers
- 40 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Cancer Recurrent
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
The hypothesis of the study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC. Characters of the patients: list item one: 168 patients, median age 48 years (range 16-75 years） proven…
- Trial name
- NCT02113423
- Testing
- 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fujian Cancer Hospital
Recurrent Brain Neoplasm
Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy
This pilot clinical trial studies the side effects and best dose of radiation therapy in patients with brain tumors that have come back after previous treatment with radiation therapy.
- Trial name
- NCT02698254
- Testing
- Bevacizumab, Quality-of-Life Assessment, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Intrinsic Pontine Glioma
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
Prospective, non-blinded, randomised two cohorts study on the efficacy of two different radiotherapy schedule for DIPG by using the same concomitant and post-radiotherapy systemic treatment.
- Trial name
- DIPG (NCT03620032)
- Testing
- Nimotuzumab, Vinorelbine, Radiotherapy
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NSCLC
Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.
Patients with lung cancer may develop a second primary tumor or recurrent disease after previous radiotherapy. Surgical salvage therapy is the mainstay of therapeutic options.
- Trial name
- NCT02029222
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht Radiation Oncology
Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent…
- Conditions
- Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- RETICULA-NPC (NCT04921995)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University